Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 30, 2017
Pharmacy Choice - News - Generic Drugs - May 30, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/22/17 - Biosimilars Insulin Market Foreseen to Grow Exponentially over 2016 2024 : Persistence Market Research
This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim..
5/22/17 - Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus
LONDON, UK/ ACCESSWIRE/ May 22, 2017/ Active Wall St. blog coverage looks at the headline from Sanofi as the Company announced on May 19, 2017, that the Committee for Medicinal Products for Human Use of the European Medicines Agency had adopted a positive opinion for the marketing authorization of Insulin lispro Sanofi . One of Sanofi's competito
5/22/17 - Elite Pharmaceuticals Acquires Trimipramine ANDA
Elite Pharmaceuticals, Inc., today announced the acquisition of an approved and currently marketed Abbreviated New Drug Application for Trimipramine Maleate Capsules 25, 50 and 100 mg, from Mikah Pharma, LLC. Reddy s Laboratories, Inc.,, will market and sell the Trimipramine products. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical c
5/22/17 - FUJIFILM KYOWA KIRIN BIOLOGICS Announces Marketing Authorisation Application for FKB327 Accepted for Review by European Medicines Agency
FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. announces that on May 18, 2017, the European Medicines Agency has accepted for review the Marketing Authorisation Application for FKB327, an adalimumab biosimilar candidate to the fully human anti-TNF-* 1 monoclonal antibody, Humira . In December 2014, Fujifilm Kyowa Kirin Biologics began a Phase 3 globa
5/22/17 - Granules India to expand pharmaceutical operation in Fairfax
Granules India Ltd. is planning to invest $35 million to expand its pharmaceutical research and development and manufacturing operation in Fairfax County. Granules India is headquartered in Hyderabad, India. "Granules Pharmaceuticals Inc. will focus on developing complex generic products by leveraging in-house technology that will increase...
5/22/17 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 18298) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Oncologic Drugs Advisory Committee to discuss biologics license application 125545, for a proposed biosimilar to Amgen Inc.' s Epogen/Procrit, submitted by Hospira Inc., a Pfizer company, for the treatment of anemia. LOCATION: FDA White Oak Campus, 1090
5/22/17 - Physician Groups Applaud FDA for Thoughtful Draft Guidance on Interchangeability, Urge for Robust Data to Demonstrate Biosimilarity
As FDA continues to develop the draft guidance, BPC urges the agency to promote transparency and patient safety by paying particular attention to the data, including robust clinical switching studies, required to demonstrate interchangeability. On Friday, six groups representing a broad spectrum of physicians who prescribe biologics Alliance for
5/22/17 - Reports Outline Oncology Study Results from Sungkyunkwan University School of Medicine (Clinical development of CT-P10 and other biosimilar cancer...
Reports Outline Oncology Study Results from Sungkyunkwan University School of Medicine. Our news journalists obtained a quote from the research from the Sungkyunkwan University School of Medicine, "To receive approval, a biosimilar must show no clinically meaningful differences from the reference product in terms of efficacy or safety.
5/22/17 - Restrictions on Pharmaceutical Salespeople's Detailing Calls Reduce Physicians Prescribing of Detailed Drugs in Favor of Generics
Do limits on how pharmaceutical sales representatives market their products to physicians change the prescribing behavior of those physicians?
5/22/17 - Study Results from University Hospital Provide New Insights into Crohn's Disease [Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in...
By a News Reporter-Staff News Editor at Clinical Trials Week Investigators publish new report on Digestive System Diseases and Conditions- Crohn's Disease. According to news originating from Seville, Spain, by NewsRx correspondents, research stated, "CT-P13 is a biosimilar of Remicade, an agent approved in some countries for use in inflammatory b
5/22/17 - Vizient, Inc. Submits Comments to the FDA about Biosimilar Interchangeability, Looks Forward to Working toward Lowering Drug Costs
On May 19, 2017, Vizient, Inc. submitted comments to the Food and Drug Administration regarding its notice Considerations on Demonstration Interchangeability with a Reference Product.. Vizient appreciates the FDA s ongoing development and implementation of the provisions of the Biologics Price Competition and Innovation Act of 2009.
5/21/17 - 5 Top NASDAQ Biotech Stocks: Nature's Sunshine Gained 31.40 Percent
Last week the Congressional Budget Office revealed it would be sharing the official score of the GOP s recently passed healthcare bill this week, the lack of this score was a big criticism of the bill passed by Congress. New FDA head Scott Gottlieb gave his first speech to the agency as his duties commence, he pointed to the opioid crisis as one
5/20/17 - GeneriCo, LLC Prevails in Inter Partes Review of United States Patent 8,865,688 [Daily Tribune (Bahrain)]
-GeneriCo, LLC, a global specialty generic drug company, today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688. Along with our IPR partner Flat Line Capital, LLC, we are pleased tha
5/19/17 - Acute Market Reports: 2017 Global market Demand Generic Drug Market - Global Industry Analysis, Market Size, Share, Growth, Trend, Market Capacity, Production, Revenue, Price and Gross Margin and Forecast 2022 by QY Research Reports
The United States Generic Drug Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Generic Drug industry. The Generic Drug market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status. The report focuses on
5/19/17 - AMCP Joins 10 Organizations in Joint Comment Letter to the FDA on Draft Interchangeability Guidance
All of the undersigned groups share the FDA's deep commitment to the development of a robust biosimilars market for patients, and greatly appreciate all the work the agency has done in creating certainty around the approval pathway created by the Biologics Price Competition and Innovation Act, including the long anticipated proposed guidance detail
5/19/17 - GE'S FLEXFACTORY TO HELP DR REDDY'S CUT COSTS BY HALF
Drug company Dr Reddy's Laboratories has teamed up with global medical technologies company GE Healthcare, which will provide DRL with flexible manufacturing platform FlexFactory to produce biopharmaceuticals swiftly. FlexFactory helps biopharmaceuticals manufacturers in significantly lowering the costs of capital and operating expanses by up...
5/19/17 - GeneriCo, LLC Prevails in Inter Partes Review of United States Patent 8,865,688
GeneriCo, LLC, a global specialty generic drug company, today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688. Along with our IPR partner Flat Line Capital, LLC, we are pleased
5/19/17 - How These Generic Drugs Stocks are Faring? MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma
Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Drugs- Generic equities this morning: MYOS RENS Technology Inc., Akari Therapeutics PLC, Flexion Therapeutics Inc., and Zynerba Pharmaceuticals Inc.. Cedar Knolls, New Jersey- based MYOS RENS Technology Inc.' s stock finished Thursday's session 2.62% lo
5/19/17 - New Findings on Inflammatory Bowel Disease from Celltrion Inc Summarized (Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13:...
By a News Reporter-Staff News Editor at Drug Week Current study results on Digestive System Diseases and Conditions- Inflammatory Bowel Disease have been published. According to news reporting out of Incheon, South Korea, by NewsRx editors, research stated, "CT-P13 is the first biosimilar monoclonal antibody to infliximab, and was recently approv
5/19/17 - Rep. Bilirakis Applauds Progress on Drug Prices, Public Health Bills
Gus Bilirakis, R- Fla., issued the following news release:. Gus Bilirakis applauded progress made on legislation he championed to lower the price of prescription medication, and reauthorize research programs for congenital heart disease and sickle cell disease. The bills were approved by the Energy and Commerce Subcommittee on Health, and will next
5/19/17 - Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
Paris, France- May 19, 2017- Sanofi announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of Insulin lispro Sanofi . CHMP recommended the use of Insulin lispro Sanofi to treat adults and children who have diabetes and need insulin
5/19/17 - Supply Of Pharmaceutical Products [TendersInfo (India)]
Contract notice: Supply of Pharmaceutical products. Supply number is comprising the following drugs: Invitation to tender: 1, ATC code: N02AE01, Generic Name: Buprenorphine, Pharmaceutical form: Resoribl., Subling., Strength: 0.2 mg, Unit Value: 1.2 mg, Quantity in units 3 483rd The above medicaments provided independently of the drugs under the ot
5/19/17 - Yes, Missouri, there is bipartisanship in Congress [St. Louis Post-Dispatch]
May 19 WASHINGTON St. Louis- area members of Congress have signed onto a range of bills with bipartisan sponsorship, and some have begun passing legislative hurdles. Susan Collins, R- Maine, are pushing legislation that would give the Food and Drug Administration more authority to counter sudden spikes in prescription drug prices by improving t
5/18/17 - Bilirakis Applauds Progress on Drug Prices, Public Health Bills
Washington, D.C.- Today, U.S. Rep. The bills were approved by the Energy and Commerce Subcommittee on Health, and will next be considered by the entire Energy and Commerce Committee before reaching the House floor. Please click here for more information on the bills: the FDA Reauthorization Act, the Congenital Heart Futures Reauthorization Act, and
5/18/17 - Biosimilar Insulin Market Access Report 2017: Uptake of Biosimilar Insulin Varies Across EU Markets as the EMA Does Not Determine Interchangeability - Research and Markets
Research and Markets has announced the addition of the "Biosimilar Insulin Market Access" report to their offering. Insights and strategic recommendations U.S payers are adopting a wait-and-see approach for biosimilar Basaglar Bibliography. Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415